Postmenopausal clinical trials

Explore recruiting postmenopausal clinical trials.

Recruiting postmenopausal studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Postmenopausal trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis

Czechia, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mineral Density

Bulgaria, Estonia, Poland, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis

France

Therapeutic use (Phase IV) EU CTIS Study details

Is there an effect of local vaginal estrogen treatment on the hemostatic parameters in postmenopausal women?

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis

Czechia, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.

Italy

Therapeutic use (Phase IV) EU CTIS Study details

Postmenopausal trials by city

Postmenopausal in Toronto Postmenopausal in Vancouver Postmenopausal in Montreal Postmenopausal in Calgary Postmenopausal in Edmonton Postmenopausal in Ottawa Postmenopausal in Winnipeg Postmenopausal in Quebec City Postmenopausal in Hamilton Postmenopausal in Kitchener Postmenopausal in London Postmenopausal in Halifax Postmenopausal in New York Postmenopausal in Los Angeles Postmenopausal in Chicago Postmenopausal in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease